Risk Factors In Coronary Artery Disease

Promoting developments in the diagnosis, prevention, and treatment of coronary artery disease, this reference furnishes the latest information on new and emerging risk factors for atherothrombotic vascular disorders-analyzing lipid-related and psychosocial risk factors, the genetic aspects of disease, the potential role of infection and inflammatio

The Social Security Administration (SSA) uses a screening tool called the Listing of Impairments to identify claimants who are so severely impaired that they cannot work at all and thus immediately qualify for benefits. In this report, the IOM makes several recommendations for improving SSA's capacity to determine disability benefits more quickly and efficiently using the Listings.

Pathophysiology of Cardiovascular Disease has been divided into four sections that focus on heart dysfunction and its associated characteristics (hypertrophy, cardiomyopathy and failure); vascular dysfunction and disease; ischemic heart disease; and novel therapeutic interventions. This volume is a compendium of different approaches to understanding cardiovascular disease and identifying the proteins, pathways and processes that impact it.

This book provides an overview of the etiology of coronary artery disease and focuses on the main therapies and drug interventions currently available. It highlights drug pharmacology and therapeutic challenges, with a special emphasis on the underlying principles of available therapeutics and the on-going development of drugs for coronary artery disease. The book is divided into eight chapters, the first of which describes the classical mechanism of coronary artery disease and its clinical presentations. Chapter 2 lists the principles of and related evidence on the prevention and treatment of coronary artery disease. This includes diet and lifestyle management, and guidelines for the treatment of acute coronary syndrome and stable coronary artery disease. In turn, Chapter 3 describes revascularization treatments, covering percutaneous coronary interventions, coronary artery bypass grafts and thrombolysis. This chapter also addresses the main therapeutic challenges. The following chapters provide an overview of three major categories of coronary artery disease drugs, which target thrombosis (Chapter 4), lipid metabolism (Chapter 5), and hypertension (Chapter 6). Heart failure constitutes the major health burden in the late stage of coronary artery disease; accordingly, current heart failure therapeutics and related drug pharmacology are described in Chapter 7. In closing, Chapter 8 provides a summary of on-going clinical trials for coronary artery disease drug development and discusses a number of promising areas in which intensive research into new therapeutics is being pursued. Given its scope, the book will be of interest to clinicians, medical students and research scientists, as well as to pharmaceutical professionals who are seeking new therapies and drugs for coronary artery disease and related disorders.

The book "From Hypertension to Heart Failure" will cover new aspects of the treatment of hypertension, arrhythmias, heart failure and coronary artery diseases. The topics will include new pathophysiological findings, the theoretical background of pharmacological treatment, results of the latest studies, and practical guidelines for treatment. Case reports will make the book applicable for a broad readership of general internists. The therapy of heart failure with betablockers is one of the most controversially discussed topics in cardiovascular medicine. Therefore, the book will critically deal with this new form of therapy for this disabling condition.

Most of us want to live a long, healthy life, but how do we do that? Drawing upon lessons from his own life, Mayo Clinic cardiologist Stephen Kopecky offers a holistic, evidence-based approach to preventing common diseases and chronic illnesses and living a longer life of pleasure and purpose. In the past century, the leading causes of death around the world have shifted from infectious diseases to long-term chronic illnesses. What’s killing us today isn’t so much flu or tuberculosis, but heart disease and cancer. In fact, more than 1.2 million Americans die from these two diseases each year. Paradoxically, these chronic diseases are a consequence of living longer than ever. But even if we’re living longer, are we living better? The overwhelming number of people now living under the burden of chronic illness indicates otherwise. After surviving two bouts of cancer, Dr. Stephen Kopecky, M.D set out to discover the behaviors people can adopt to live longer lives free of chronic illnesses and diseases. What he discovered was that the answer lies in just six habits that require small changes to your daily life, but reap big results long-term. From adopting better diet and exercise habits to managing stress and sleep, these behaviors will not only preserve your health, they can improve your quality of living and extend your life. The secret, however, lies not just in the steps themselves but in how you accomplish them. This book offers in-depth insights on: The best foods to eat and why Increasing physical activity and improving fitness Why your sleep habits matter The dangers of stress and what to do about them The true impact of alcohol and tobacco on our bodies How to make changes that will last a lifetime After 30 years of research in the field of cardiovascular disease prevention, Dr. Kopecky is sharing what he’s learned from his practice and own personal experience about staying healthy, preventing chronic illnesses, and living younger longer.

Chronic diseases are common and costly, yet they are also among the most preventable health problems. Comprehensive and accurate disease surveillance systems are needed to implement successful efforts which will reduce the burden of chronic diseases on the U.S. population. A number of sources of surveillance data--including population surveys, cohort studies, disease registries, administrative health data, and vital statistics--contribute critical information about chronic disease. But no central surveillance system provides the information needed to analyze how chronic disease impacts the U.S. population, to identify public health priorities, or to track the progress of preventive efforts. A Nationwide Framework for Surveillance of Cardiovascular and Chronic Lung Diseases outlines a conceptual framework for building a national chronic disease surveillance system focused primarily on cardiovascular and chronic lung diseases. This system should be capable of providing data on disparities in incidence and prevalence of the diseases by race, ethnicity, socioeconomic status, and geographic region, along with data on disease risk factors, clinical care delivery, and functional health outcomes. This coordinated surveillance system is needed to integrate and expand existing information across the multiple levels of decision making in order to generate actionable, timely knowledge for a range of stakeholders at the local, state or regional, and national levels. The recommendations presented in A Nationwide Framework for Surveillance of Cardiovascular and Chronic Lung Diseases focus on data collection, resource allocation, monitoring activities, and implementation. The report also recommends that systems evolve along with new knowledge about emerging risk factors, advancing technologies, and new understanding of the basis for disease. This report will inform decision-making among federal health agencies, especially the Department of Health and Human Services; public health and clinical practitioners; non-governmental organizations; and policy makers, among others.